secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001829126-23-003950
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharmaceuticals receives Nasdaq extension to Oct 2, 2023 to regain compliance with $2.5M equity requirement
--------------------------------------------------------------------------------

- Stockholders' equity reported at $1.363M, below Nasdaq's $2.5M minimum.
- Nasdaq grants 180-day extension to October 2, 2023 to demonstrate compliance.
- Company submitted a compliance plan on May 22, 2023.
- Failure to comply by Oct 2 or upon filing 2023 10-K may lead to delisting.
- Delisting would reduce liquidity, market price, and access to financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/0001829126-23-003950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-003950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer